Mannitol 15% side effects, by duration, gender and age (a phase IV clinical study of FDA data)

female:

1. Bradycardia (abnormally slow heart action)
2. Drug ineffective
3. Haemorrhagic diathesis (bleeding tendency)
4. Toxic epidermal necrolysis (a rare, life-threatening skin condition that is usually caused by a reaction to drugs causes wide spread skin destruction)

male:

1. Anaemia (lack of blood)
2. Disease progression
3. International normalised ratio increased
4. Visual impairment

0-1:

n/a

2-9:

1. International normalised ratio increased

10-19:

n/a

20-29:

1. Anaemia (lack of blood)
2. Visual impairment

30-39:

n/a

40-49:

1. Bradycardia (abnormally slow heart action)

50-59:

n/a

60+:

1. Disease progression
2. Drug ineffective
3. Haemorrhagic diathesis (bleeding tendency)

< 1 month:

1. Bradycardia (abnormally slow heart action)
2. Nausea (feeling of having an urge to vomit)
3. Toxic epidermal necrolysis (a rare, life-threatening skin condition that is usually caused by a reaction to drugs causes wide spread skin destruction)

1 - 6 months:

n/a

6 - 12 months:

n/a

1 - 2 years:

n/a

2 - 5 years:

n/a

5 - 10 years:

n/a

10+ years:

n/a

not specified:

1. Altered state of consciousness (altered state of mind)
2. Anaemia (lack of blood)
3. Disease progression
4. Drug ineffective
5. Haemorrhagic diathesis (bleeding tendency)
6. International normalised ratio increased
7. Visual impairment